Modafinil/armodafinil in the treatment of narcolepsy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Modafinil has been available in the USA since 1998 and is now regarded as the first-line therapy for the treatment of excessive sleepiness associated with narcolepsy. Modafinil does not help cataplexy or other ancillary features of narcolepsy, such as hypnagogic hallucinations or sleep paralysis. In 2004, the indication for modafinil was expanded to include the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). Since that time modafinil has become the most widely prescribed agent in the U.S. for excessive sleepiness of all types. In 2007, armodafinil, the r-enantiomer of modafinil (racemic), was approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). However, armodafinil is not yet available in pharmacies for use.

Original languageEnglish (US)
Title of host publicationNarcolepsy: A Clinical Guide
PublisherSpringer New York
Pages287-294
Number of pages8
ISBN (Print)9781441908537
DOIs
StatePublished - 2010

Fingerprint

Narcolepsy
Obstructive Sleep Apnea
Circadian Rhythm Sleep Disorders
Sleep Paralysis
Cataplexy
Pharmacies
Hallucinations
modafinil
armodafinil

Keywords

  • Armodafinil
  • Modafinil
  • Narcolepsy
  • Sleepiness

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thorpy, M. J. (2010). Modafinil/armodafinil in the treatment of narcolepsy. In Narcolepsy: A Clinical Guide (pp. 287-294). Springer New York. https://doi.org/10.1007/978-1-4419-0854-4_25

Modafinil/armodafinil in the treatment of narcolepsy. / Thorpy, Michael J.

Narcolepsy: A Clinical Guide. Springer New York, 2010. p. 287-294.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thorpy, MJ 2010, Modafinil/armodafinil in the treatment of narcolepsy. in Narcolepsy: A Clinical Guide. Springer New York, pp. 287-294. https://doi.org/10.1007/978-1-4419-0854-4_25
Thorpy MJ. Modafinil/armodafinil in the treatment of narcolepsy. In Narcolepsy: A Clinical Guide. Springer New York. 2010. p. 287-294 https://doi.org/10.1007/978-1-4419-0854-4_25
Thorpy, Michael J. / Modafinil/armodafinil in the treatment of narcolepsy. Narcolepsy: A Clinical Guide. Springer New York, 2010. pp. 287-294
@inbook{9653444e9eb24ba4b017f33f3bb0a481,
title = "Modafinil/armodafinil in the treatment of narcolepsy",
abstract = "Modafinil has been available in the USA since 1998 and is now regarded as the first-line therapy for the treatment of excessive sleepiness associated with narcolepsy. Modafinil does not help cataplexy or other ancillary features of narcolepsy, such as hypnagogic hallucinations or sleep paralysis. In 2004, the indication for modafinil was expanded to include the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). Since that time modafinil has become the most widely prescribed agent in the U.S. for excessive sleepiness of all types. In 2007, armodafinil, the r-enantiomer of modafinil (racemic), was approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). However, armodafinil is not yet available in pharmacies for use.",
keywords = "Armodafinil, Modafinil, Narcolepsy, Sleepiness",
author = "Thorpy, {Michael J.}",
year = "2010",
doi = "10.1007/978-1-4419-0854-4_25",
language = "English (US)",
isbn = "9781441908537",
pages = "287--294",
booktitle = "Narcolepsy: A Clinical Guide",
publisher = "Springer New York",

}

TY - CHAP

T1 - Modafinil/armodafinil in the treatment of narcolepsy

AU - Thorpy, Michael J.

PY - 2010

Y1 - 2010

N2 - Modafinil has been available in the USA since 1998 and is now regarded as the first-line therapy for the treatment of excessive sleepiness associated with narcolepsy. Modafinil does not help cataplexy or other ancillary features of narcolepsy, such as hypnagogic hallucinations or sleep paralysis. In 2004, the indication for modafinil was expanded to include the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). Since that time modafinil has become the most widely prescribed agent in the U.S. for excessive sleepiness of all types. In 2007, armodafinil, the r-enantiomer of modafinil (racemic), was approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). However, armodafinil is not yet available in pharmacies for use.

AB - Modafinil has been available in the USA since 1998 and is now regarded as the first-line therapy for the treatment of excessive sleepiness associated with narcolepsy. Modafinil does not help cataplexy or other ancillary features of narcolepsy, such as hypnagogic hallucinations or sleep paralysis. In 2004, the indication for modafinil was expanded to include the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). Since that time modafinil has become the most widely prescribed agent in the U.S. for excessive sleepiness of all types. In 2007, armodafinil, the r-enantiomer of modafinil (racemic), was approved for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). However, armodafinil is not yet available in pharmacies for use.

KW - Armodafinil

KW - Modafinil

KW - Narcolepsy

KW - Sleepiness

UR - http://www.scopus.com/inward/record.url?scp=84892861721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892861721&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0854-4_25

DO - 10.1007/978-1-4419-0854-4_25

M3 - Chapter

SN - 9781441908537

SP - 287

EP - 294

BT - Narcolepsy: A Clinical Guide

PB - Springer New York

ER -